Tim Chiang now sees a bigger per share value for ARDX’s tenapanor in the IBS-C market.
Ardelyx’s drug tenapanor gets closer to FDA approval; Cantor’s Mara Goldstein weighs in.
Tenapanor is a viable drug in the treatment of IBS-C, says Cantor’s Mara Goldstein.
